Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Oncology Patients Receiving Chemotherapy 1Neoplasms 1Lung Neoplasms 1Hypersensitivity 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Cetirizine × Clear all
NCT06039137 2024-09-25

H1-Switch

Erasmus Medical Center

Completed
395 enrolled

Hypersensitivity, Neoplasms

NCT04189588 2023-10-06

versus

TerSera Therapeutics LLC

Phase 2 Completed
34 enrolled 11 charts

Oncology Patients Receiving Chemotherapy

NCT04237090 2020-10-12

PREMED-F1

Ciusss de L'Est de l'Île de Montréal

Phase 3 Completed
27 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡